Organon & Co. (OGN) Stock Price, News & Analysis

Company Overview

Organon & Co. is a global healthcare company focused primarily on women’s health, biosimilars and a portfolio of established medicines. The company develops, manufactures and commercializes prescription products designed to address a range of health needs, with an emphasis on expanding access to treatments in markets around the world.

Its women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines used in areas including fertility and reproductive health. Organon also markets established brands in categories such as cardiovascular disease, respiratory health, dermatology, pain management and gastroenterology. Its biosimilars business provides lower-cost alternatives to certain biologic medicines and includes products developed through internal programs and commercial partnerships.

Organon was established as an independent, publicly traded company in June 2021 after being separated from Merck & Co. The company is headquartered in Jersey City, New Jersey, and serves patients and healthcare providers across international markets through its commercial and manufacturing operations.

Key Stats

• Today's Range: $13.73 to $13.75
• 50-Day Range: $13.54 to $13.78
• 52-Week Range: $5.69 to $13.78
• Volume: 1.95 million shs
• Average Volume: 2.29 million shs
• Market Capitalization: $3.61 billion
• P/E Ratio: 4.57
• Dividend Yield: 0.58%
• Price Target: $11.40
• Consensus Rating: Reduce

Organon & Co. Stock Analysis - MarketRank™

Organon & Co. scored higher than 25% of companies evaluated by MarketBeat, and ranked 754th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Organon & Co. has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on no strong buy ratings, no buy ratings, 5 hold ratings, and 2 sell ratings.

Downside Risk

Organon & Co. has a consensus price target of $11.40, representing about 17.1% downside from its current price of $13.75.

Amount of Analyst Coverage

Organon & Co. has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 6.50%

Earnings Growth

Earnings for Organon & Co. are expected to grow by 6.50% in the coming year, from $3.23 to $3.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organon & Co. is 17.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organon & Co. is 17.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.67.

Price to Earnings Growth Ratio

Organon & Co. has a PEG Ratio of 1.27. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Organon & Co. has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.79% of the float of Organon & Co. has been sold short.

Short Interest Ratio / Days to Cover

Organon & Co. has a short interest ratio ("days to cover") of 5.53.

Change versus previous month

Short interest in Organon & Co. has recently increased by 5.00%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Organon & Co. has a dividend yield of 0.58%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Organon & Co. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Organon & Co. is 10.39%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Organon & Co. will have a dividend payout ratio of 2.33% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Organon & Co. has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

Search Interest

3 people have searched for OGN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organon & Co. insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.62% of the stock of Organon & Co. is held by insiders.

Percentage Held by Institutions

77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/30/2026
• Record date for 9/10 Dividend: 8/14/2026
• Ex-Dividend for 9/10 Dividend: 8/14/2026
• Dividend Payable: 9/10/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:OGN
• CIK: 1821825
• Web: www.organon.com
• Phone: (551) 430-6000
• Fax: N/A
• Employees: 10,000
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Organon & Co.: $11.40
• High Price Target: $14.00
• Low Price Target: $8.00
• Potential Upside/Downside: -17.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.77
• Trailing P/E Ratio: 17.85
• Forward P/E Ratio: 4.26
• P/E Growth: 1.27
• Net Income: $187 million
• Net Margins: 3.41%
• Pretax Margin: 8.01%
• Return on Equity: 88.97%
• Return on Assets: 6.03%

Debt

• Debt-to-Equity Ratio: 8.43
• Current Ratio: 1.95
• Quick Ratio: 1.44

Sales & Book Value

• Annual Sales: $6.13 billion
• Price / Sales: 0.59
• Cash Flow: $5.80 per share
• Price / Cash Flow: 2.37
• Book Value: $2.89 per share
• Price / Book: 4.76

Miscellaneous

• Outstanding Shares: 262,609,000
• Free Float: 258,355,000
• Market Cap: $3.61 billion
• Optionable: Not Optionable
• Beta: 1.55